Онкология. Журнал им. П. А. Герцена, 2, 2016

ОНКОЛОГИЯ. ЖУРНАЛ им. П.А. ГЕРЦЕНА, 2, 2016
71
smooth muscle cells in vitro and in vivo. 
Mol Med
. 2000;6(11):983-
991.
5. Lee SJ, Kim HS, Yu R, Bae KH, Stantz KM, Lee SJ et al. Novel 
prostate-specific promoter derived from PSA and PSMA enhanc-
ers. 
Mol Ther. 
2002;6(3):415-421.
6. Smith MJ, Rousculp MD, Goldsmith KT, Curiel DT, Garver RI. 
Surfactant protein A-directed toxin gene kills lung cancer cells in 
vitro. 
Hum Gene Ther.
1994;5(1):29-35.
7. Strayer MS, Guttentag SH, Ballard PL. Targeting type II and Clara 
cells for adenovirus-mediated gene transfer using the surfactant 
protein B promoter. 
Am J Respir Cell Mol Biol
. 1998;18(1):1-11. 
8. Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-
Margoulis O et al. Aberrant intestinal expression and allelic vari-
ants of mucin genes associated with inflammatory bowel disease. 
J 
Mol Med
. 2006;84(12):1055-1066.
9. Kuriyama S, Yoshikawa М, Ishizaka S, Tsujli T, Ikenaka K, Kaga-
wa T et al. A potential approach for gene therapy targeting hepato-
ma using a liver-specific promoter on a retroviral vector. 
Cell Struct 
Funct
. 1991;16(6):503-510.
10. Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV et 
al. The human survivin promoter: a novel transcriptional targeting 
strategy for treatment of glioma. 
J Neurosurg
. 2006;104(4):583-
592. 
11. Gu J, Fang B. Telomerase promoter-driven cancer gene therapy. 
Cancer Biol Ther
. 2003;2(4,Suppl.1):S64-S70.
12. Thomas SM, Grandis JR. The current state of head and neck can-
cer gene therapy. 
Hum Gene Ther. 
2009;20(12):1565-1575. 
doi:10.1089/hum.2009.163.
13. Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery meth-
ods. 
Curr Pharm Biotechnol. 
2013;14(1):46-60.
14. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the 
use of viral vectors for gene therapy. 
Nat Rev Genet
. 2003;4(5):346-
358. 
15. Yuan Z, Pastoriza J, Quinn T, Libutti S. Targeting tumor vascu-
lature using adeno-associated virus page vector coding tumor ne-
crosis factor-a. In: Lattime EC, Gerson SL, eds. 
Gene therapy of 
cancer
. 3rd ed. San Diego (CA): Elsevier; 2013:19-33. 
doi:10.1038/cgt.2012.83.
16. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, 
Berry CC et al. Efficacy of gene therapy for X-linked severe 
combined immunodeficiency. 
N Engl J Med.
2010;363(4):355-364.
doi:10.1056/NEJMoa1000164.
17. Bangari DS, Mittal SK. Current strategies and future directions 
for eluding adenoviral vector immunity. 
Curr Gene Ther
. 
2006;6(2):215-226.
18. Palmer DJ, Ng P. Helper-dependent adenoviral vectors for gene 
therapy. 
Hum Gene Ther. 
2005;16(1):1-16.
19. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene 
transfer with a helper-dependent adenoviral vector. 

жүктеу/скачать 260,06 Kb.

Достарыңызбен бөлісу: